Literature DB >> 15615744

Iodide iontophoresis as a treatment for dry eye syndrome.

J Horwath-Winter1, O Schmut, E-M Haller-Schober, A Gruber, G Rieger.   

Abstract

BACKGROUND/AIMS: Among the causes related to the development or perpetuation and aggravation of dry eye disease, oxidative reactions may have a role in the pathogenesis of this disorder. Antioxidants, such as iodide, have shown a strong effect in preventing the oxidative damage to constituents of the anterior part of the eye. In this clinical trial the effectiveness of iodide iontophoresis and iodide application without current in moderate to severe dry eye patients was compared.
METHODS: 16 patients were treated with iodide iontophoresis and 12 patients with iodide application without current for 10 days. Subjective improvement, frequency of artificial tear application, tear function parameters (break up time, Schirmer test without local anaesthesia), vital staining (fluorescein and rose bengal staining) as well as impression cytology of the bulbar conjunctiva were evaluated before treatment, 1 week, 1 month, and 3 months after treatment.
RESULTS: A reduction in subjective symptoms, frequency of artificial tear substitute application, and an improvement in certain tear film and ocular surface factors could be observed in both groups. A stronger positive influence was seen after application of iodide with current (iontophoresis), as observed in a distinct improvement in break up time, fluorescein and rose bengal staining, and in a longer duration of this effect compared with the non-current group. No significant change in Schirmer test results and impression cytology were observed in both groups.
CONCLUSIONS: Iodide iontophoresis has been demonstrated to be a safe and well tolerated method of improving subjective and objective dry eye factors in patients with ocular surface disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15615744      PMCID: PMC1772481          DOI: 10.1136/bjo.2004.048314

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  49 in total

1.  [Comparative studies on radioiodine distribution in the eye after iontophoretic and intravenous administration].

Authors:  H POMMER; F TRICHTEL
Journal:  Albrecht Von Graefes Arch Ophthalmol       Date:  1956

2.  [The enrichment of the eye with iodine by iontophoresis].

Authors:  H POMMER
Journal:  Wien Klin Wochenschr       Date:  1955-08-19       Impact factor: 1.704

3.  Superoxide-dependent production of hydroxyl radical catalyzed by iron-EDTA complex.

Authors:  J M McCord; E D Day
Journal:  FEBS Lett       Date:  1978-02-01       Impact factor: 4.124

4.  Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats.

Authors:  F F Behar-Cohen; J M Parel; Y Pouliquen; B Thillaye-Goldenberg; O Goureau; S Heydolph; Y Courtois; Y De Kozak
Journal:  Exp Eye Res       Date:  1997-10       Impact factor: 3.467

5.  Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells.

Authors:  Caroline Debbasch; Stéphanie Bruneau De La Salle; Françoise Brignole; Patrice Rat; Jean-Michel Warnet; Christophe Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-11       Impact factor: 4.799

6.  Staging of conjunctival squamous metaplasia by impression cytology.

Authors:  S C Tseng
Journal:  Ophthalmology       Date:  1985-06       Impact factor: 12.079

7.  Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.

Authors:  F F Behar-Cohen; A El Aouni; S Gautier; G David; J Davis; P Chapon; J M Parel
Journal:  Exp Eye Res       Date:  2002-01       Impact factor: 3.467

8.  Transscleral and transcorneal iontophoresis of ketoconazole in the rabbit eye.

Authors:  R Grossman; D A Lee
Journal:  Ophthalmology       Date:  1989-05       Impact factor: 12.079

9.  Oxidative damage to extracellular fluids by ozone and possible protective effects of thiols.

Authors:  A Van der Vliet; C A O'Neil; J P Eiserich; C E Cross
Journal:  Arch Biochem Biophys       Date:  1995-08-01       Impact factor: 4.013

10.  Iodine distribution in a porcine eye model following iontophoresis.

Authors:  G Rieger; R Winkler; W Buchberger; M Moser
Journal:  Ophthalmologica       Date:  1995       Impact factor: 3.250

View more
  6 in total

Review 1.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

2.  The effect of iodide iontophoresis on the antioxidative capacity of the tear fluid.

Authors:  Gebhard Rieger; Manfred Klieber; Wolfgang Schimetta; Werner Pölz; Sirid Griebenow; Rudolf Winkler; Jutta Horwath-Winter; Otto Schmut; Birgit Spitzer-Sonnleitner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-23       Impact factor: 3.117

Review 3.  Recent advances in ophthalmic drug delivery.

Authors:  Uday B Kompella; Rajendra S Kadam; Vincent H L Lee
Journal:  Ther Deliv       Date:  2010-09

4.  Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial.

Authors:  Michael A Patane; Amy Cohen; Stephen From; Gail Torkildsen; Donna Welch; George W Ousler
Journal:  Clin Ophthalmol       Date:  2011-05-15

Review 5.  Emerging therapies for noninfectious uveitis: what may be coming to the clinics.

Authors:  Jose R Maya; Mohammad A Sadiq; Liz J Zapata; Mostafa Hanout; Salman Sarwar; Nithya Rajagopalan; Kathleen E Guinn; Yasir J Sepah; Quan Dong Nguyen
Journal:  J Ophthalmol       Date:  2014-04-24       Impact factor: 1.909

6.  A Case-Control Study on the Oxidative Balance of 50% Autologous Serum Eye Drops.

Authors:  Patrícia Ioschpe Gus; Diane Marinho; Samira Zelanis; Adriane Belló-Klein; Claudete Locatelli; Felipe Nicola; Ana Laura Kunzler; Tania Regina Gatelli Fernandes; Cristina Campos Carraro; Luciene Barbosa
Journal:  Oxid Med Cell Longev       Date:  2016-08-21       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.